Abstract

Purpose of reviewTo explore the data for and against the use of the various components of multimodal analgesia in cranial neurosurgery.Recent findingsPostcraniotomy pain is a challenging clinical problem in that analgesia must be accomplished without affecting neurologic function (i.e. 'losing the neurologic exam'). The traditional approach with low-dose opioids is often insufficient and can cause well recognized side effects. Newer multimodal analgesic approaches have proven beneficial in a variety of other surgical patient populations. The combined use of multiple nonopioid analgesics offers the promise of improved pain control and reduced opioid administration, while preserving the clinical neurologic exam. Specifically, acetaminophen and gabapentinoids should be considered for craniotomy patients, both preoperatively and postoperatively. The gabapentinoids have the added benefit of reduced nausea. Scalp blocks have moderate quality evidence supporting their use over incisional infiltration alone, with analgesia that extends into the postoperative period. Intraoperative dexmedetomidine reduces postoperative opioid requirements with the added benefit of reduced postcraniotomy hypertension. Methocarbamol, NSAIDs [both nonspecific cyclooxygenase (COX) 1 and 2 inhibitors and specific COX-2 inhibitors], ketamine, and intravenous lidocaine require further data regarding safety and efficacy in craniotomy patients.SummaryOpioids are the mainstay for treating acute postcraniotomy pain but should be minimized. The evidence to support a multimodal approach is growing; neuroanesthesiologists and neurosurgeons should seek to incorporate multimodal analgesia into the perioperative care of craniotomy patients. Preoperative and postoperative gabapentin and acetaminophen, intraoperative dexmedetomidine, and scalp blocks over incisional infiltration have the most data for benefit, with good safety profiles. Further research is needed to define the safety, efficacy, and dosing parameters for NSAIDs including COX-2 inhibitors, methocarbamol, ketamine, and intravenous lidocaine in cranial neurosurgery.

Original languageEnglish (US)
Pages (from-to)592-599
Number of pages8
JournalCurrent Opinion in Anaesthesiology
Volume32
Issue number5
DOIs
StatePublished - Oct 1 2019

Fingerprint

Craniotomy
Analgesia
Cyclooxygenase 2 Inhibitors
Methocarbamol
Opioid Analgesics
Nervous System
Dexmedetomidine
Ketamine
Neurosurgery
Non-Steroidal Anti-Inflammatory Agents
Acetaminophen
Lidocaine
Scalp
Safety
Non-Narcotic Analgesics
Perioperative Care
Pain
Cyclooxygenase 1
Acute Pain
Postoperative Period

Keywords

  • analgesia
  • craniotomy
  • multimodal
  • postoperative pain

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Multimodal analgesia for craniotomy. / Ban, Vin Shen; Bhoja, Ravi; McDonagh, David L.

In: Current Opinion in Anaesthesiology, Vol. 32, No. 5, 01.10.2019, p. 592-599.

Research output: Contribution to journalReview article

@article{62761b0e325e459c9ca457da4af9c7f1,
title = "Multimodal analgesia for craniotomy",
abstract = "Purpose of reviewTo explore the data for and against the use of the various components of multimodal analgesia in cranial neurosurgery.Recent findingsPostcraniotomy pain is a challenging clinical problem in that analgesia must be accomplished without affecting neurologic function (i.e. 'losing the neurologic exam'). The traditional approach with low-dose opioids is often insufficient and can cause well recognized side effects. Newer multimodal analgesic approaches have proven beneficial in a variety of other surgical patient populations. The combined use of multiple nonopioid analgesics offers the promise of improved pain control and reduced opioid administration, while preserving the clinical neurologic exam. Specifically, acetaminophen and gabapentinoids should be considered for craniotomy patients, both preoperatively and postoperatively. The gabapentinoids have the added benefit of reduced nausea. Scalp blocks have moderate quality evidence supporting their use over incisional infiltration alone, with analgesia that extends into the postoperative period. Intraoperative dexmedetomidine reduces postoperative opioid requirements with the added benefit of reduced postcraniotomy hypertension. Methocarbamol, NSAIDs [both nonspecific cyclooxygenase (COX) 1 and 2 inhibitors and specific COX-2 inhibitors], ketamine, and intravenous lidocaine require further data regarding safety and efficacy in craniotomy patients.SummaryOpioids are the mainstay for treating acute postcraniotomy pain but should be minimized. The evidence to support a multimodal approach is growing; neuroanesthesiologists and neurosurgeons should seek to incorporate multimodal analgesia into the perioperative care of craniotomy patients. Preoperative and postoperative gabapentin and acetaminophen, intraoperative dexmedetomidine, and scalp blocks over incisional infiltration have the most data for benefit, with good safety profiles. Further research is needed to define the safety, efficacy, and dosing parameters for NSAIDs including COX-2 inhibitors, methocarbamol, ketamine, and intravenous lidocaine in cranial neurosurgery.",
keywords = "analgesia, craniotomy, multimodal, postoperative pain",
author = "Ban, {Vin Shen} and Ravi Bhoja and McDonagh, {David L}",
year = "2019",
month = "10",
day = "1",
doi = "10.1097/ACO.0000000000000766",
language = "English (US)",
volume = "32",
pages = "592--599",
journal = "Current Opinion in Anaesthesiology",
issn = "0952-7907",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Multimodal analgesia for craniotomy

AU - Ban, Vin Shen

AU - Bhoja, Ravi

AU - McDonagh, David L

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Purpose of reviewTo explore the data for and against the use of the various components of multimodal analgesia in cranial neurosurgery.Recent findingsPostcraniotomy pain is a challenging clinical problem in that analgesia must be accomplished without affecting neurologic function (i.e. 'losing the neurologic exam'). The traditional approach with low-dose opioids is often insufficient and can cause well recognized side effects. Newer multimodal analgesic approaches have proven beneficial in a variety of other surgical patient populations. The combined use of multiple nonopioid analgesics offers the promise of improved pain control and reduced opioid administration, while preserving the clinical neurologic exam. Specifically, acetaminophen and gabapentinoids should be considered for craniotomy patients, both preoperatively and postoperatively. The gabapentinoids have the added benefit of reduced nausea. Scalp blocks have moderate quality evidence supporting their use over incisional infiltration alone, with analgesia that extends into the postoperative period. Intraoperative dexmedetomidine reduces postoperative opioid requirements with the added benefit of reduced postcraniotomy hypertension. Methocarbamol, NSAIDs [both nonspecific cyclooxygenase (COX) 1 and 2 inhibitors and specific COX-2 inhibitors], ketamine, and intravenous lidocaine require further data regarding safety and efficacy in craniotomy patients.SummaryOpioids are the mainstay for treating acute postcraniotomy pain but should be minimized. The evidence to support a multimodal approach is growing; neuroanesthesiologists and neurosurgeons should seek to incorporate multimodal analgesia into the perioperative care of craniotomy patients. Preoperative and postoperative gabapentin and acetaminophen, intraoperative dexmedetomidine, and scalp blocks over incisional infiltration have the most data for benefit, with good safety profiles. Further research is needed to define the safety, efficacy, and dosing parameters for NSAIDs including COX-2 inhibitors, methocarbamol, ketamine, and intravenous lidocaine in cranial neurosurgery.

AB - Purpose of reviewTo explore the data for and against the use of the various components of multimodal analgesia in cranial neurosurgery.Recent findingsPostcraniotomy pain is a challenging clinical problem in that analgesia must be accomplished without affecting neurologic function (i.e. 'losing the neurologic exam'). The traditional approach with low-dose opioids is often insufficient and can cause well recognized side effects. Newer multimodal analgesic approaches have proven beneficial in a variety of other surgical patient populations. The combined use of multiple nonopioid analgesics offers the promise of improved pain control and reduced opioid administration, while preserving the clinical neurologic exam. Specifically, acetaminophen and gabapentinoids should be considered for craniotomy patients, both preoperatively and postoperatively. The gabapentinoids have the added benefit of reduced nausea. Scalp blocks have moderate quality evidence supporting their use over incisional infiltration alone, with analgesia that extends into the postoperative period. Intraoperative dexmedetomidine reduces postoperative opioid requirements with the added benefit of reduced postcraniotomy hypertension. Methocarbamol, NSAIDs [both nonspecific cyclooxygenase (COX) 1 and 2 inhibitors and specific COX-2 inhibitors], ketamine, and intravenous lidocaine require further data regarding safety and efficacy in craniotomy patients.SummaryOpioids are the mainstay for treating acute postcraniotomy pain but should be minimized. The evidence to support a multimodal approach is growing; neuroanesthesiologists and neurosurgeons should seek to incorporate multimodal analgesia into the perioperative care of craniotomy patients. Preoperative and postoperative gabapentin and acetaminophen, intraoperative dexmedetomidine, and scalp blocks over incisional infiltration have the most data for benefit, with good safety profiles. Further research is needed to define the safety, efficacy, and dosing parameters for NSAIDs including COX-2 inhibitors, methocarbamol, ketamine, and intravenous lidocaine in cranial neurosurgery.

KW - analgesia

KW - craniotomy

KW - multimodal

KW - postoperative pain

UR - http://www.scopus.com/inward/record.url?scp=85071510029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071510029&partnerID=8YFLogxK

U2 - 10.1097/ACO.0000000000000766

DO - 10.1097/ACO.0000000000000766

M3 - Review article

C2 - 31306155

AN - SCOPUS:85071510029

VL - 32

SP - 592

EP - 599

JO - Current Opinion in Anaesthesiology

JF - Current Opinion in Anaesthesiology

SN - 0952-7907

IS - 5

ER -